The Global Amitriptyline Market Growth Is Accelerated By Rising Consumption
![]() |
Amitriptyline Market |
Amitriptyline is a tricyclic antidepressant used to treat
depression and neuropathic pain. It helps restore the balance of certain
natural chemicals in the brain like serotonin and norepinephrine.
The global Amitriptyline Market is estimated to be valued at
US$ 699.27 Mn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period 2024 to 2031, as highlighted
in a new report published by Coherent Market Insights.
Market key trends:
The consumption of amitriptyline has been rising globally owing to the
increasing prevalence of depression and neuropathic pain disorders. According
to WHO, depression is now the leading cause of ill health and disability
worldwide. Nearly 280 million people are living with depression. The increasing
cases of depression and chronic pain disorders have been the major factor
driving the growth of the amitriptyline market. Besides this, amitriptyline is
considered as the first line treatment option for neuropathic pain conditions
like diabetic neuropathy and post-herpetic neuralgia. This has further
augmented the demand for amitriptyline over the forecast period.
Segment Analysis
The global Amitriptyline market is dominated by the depression segment.
Amitriptyline is commonly prescribed for major depressive disorder as it is
proven to be effective for treatment-resistant depression. It helps relieve
symptoms such as depressed mood, loss of interest, feelings of guilt or low
self-worth, disturbed sleep or appetite, low energy, and poor concentration.
This makes depression the largest application segment in the Amitriptyline
market.
Key Takeaways
The global
Amitriptyline market analysis is expected to witness high growth over
the forecast period of 2024 to 2031. The global Amitriptyline Market is
estimated to be valued at US$ 699.27 Mn in 2024 and is expected to exhibit a
CAGR of 5.1% over the forecast period 2024 to 2031.
Regional analysis:
North America currently dominates the Amitriptyline market and is expected
to continue its dominance over the forecast period. High prevalence of
depression in countries like the U.S. and rising awareness about available
treatment options are major factors contributing to the region's large share.
However, Asia Pacific is projected to grow at the fastest pace owing to
increasing healthcare expenditure and growing geriatric population in countries
like China and India.
Key players:
Key players operating in the Amitriptyline market are Adani Wilmar Ltd.,
Ruchi Soya Industries Ltd, Associated British Foods plc, Archer Daniels Midland
Company, Beidahuang Group, Bunge Limited, Borges Mediterranean Group, Cargill
Incorporated, Fuji Vegetable Oil, Inc.
Get more insights on this topic: https://www.newswirestats.com/amitriptyline-market-industry-insights-trends-amitriptyline-market/
Explore more information on this topic, Please visit: https://whotimes.com/change-harmony-exploring-the-dynamic-world-of-ion-exchange-membranes-for-applications/
Comments
Post a Comment